Search Results

You are looking at 11 - 20 of 48 items for :

  • "neuroendocrine tumour" x
  • User-accessible content x
Clear All
Open access

Richard P Steeds, Vandana Sagar, Shishir Shetty, Tessa Oelofse, Harjot Singh, Raheel Ahmad, Elizabeth Bradley, Rachel Moore, Suzanne Vickrage, Stacey Smith, Ivan Yim, Yasir S Elhassan, Hema Venkataraman, John Ayuk, Stephen Rooney and Tahir Shah

Introduction Neuroendocrine tumours (NETs) of gastrointestinal origin (GI NET) synthesise and release various hormones, including 5-hydroxytryptamine (5-HT). These hormones drain from the primary lesion and local lymph node metastases via the

Open access

Stefan Schulz, Anika Mann, Benjamin Novakhov, Hugh D Piggins and Amelie Lupp

=12); cervical carcinoma ( n =13); urinary bladder carcinoma ( n =8); prostate carcinoma ( n =7); neuroendocrine tumours ( n =23); growth hormone (GH)-producing pituitary adenoma ( n =21) and pheochromocytoma ( n =5). Several of the tumours contained

Open access

Filippo Ceccato, Diego Cecchin, Michele Gregianin, Giacomo Ricci, Cristina Campi, Filippo Crimì, Marta Bergamo, Annibale Versari, Carmelo Lacognata, Federico Rea, Mattia Barbot and Carla Scaroni

covert EAS (the time span from occult to covert is described in brackets) at EAS diagnosis (baseline) or during follow-up (indicating which imaging technique was positive to localize the tumour). EAS, ectopic ACTH secretion; NET, neuroendocrine

Open access

Matilde Calanchini, Michael Tadman, Jesper Krogh, Andrea Fabbri, Ashley Grossman and Brian Shine

tool for diagnosing and the monitoring of patients with NENs ( 18 , 24 ). At present, the European Neuroendocrine Tumour Society ( 18 ), the UK and Ireland Neuroendocrine Tumour Society ( 25 ) and the North American Neuroendocrine Tumour Society ( 26

Open access

Majunath R Goroshi, Swati S Jadhav, Anurag R Lila, Rajeev Kasaliwal, Shruti Khare, Chaitanya G Yerawar, Priya Hira, Uday Phadke, Hina Shah, Vikram R Lele, Gaurav Malhotra, Tushar Bandgar and Nalini S Shah

small-cell carcinoma of lung), majority of cases of EAS are now reported to be caused by neuroendocrine tumours (NETs) that include carcinoid tumours of bronchopulmonary system, thymus, and gastrointestinal tract; pancreatic NETs; medullary thyroid

Open access

Małgorzata Fuksiewicz, Maria Kowalska, Agnieszka Kolasińska-Ćwikła, Jarosław B Ćwikła, Łukasz Sawicki, Katarzyna Roszkowska-Purska, Joanna Drygiel and Beata Kotowicz

, chromogranin A; NEN, neuroendocrine neoplasm; OS, overall survival. Discussion The most common location of neuroendocrine tumours is the digestive system (GEP-NEN GEP). The diagnosis is usually made at the advanced stage of the disease when

Open access

Yang Lv, Ning Pu, Wei-lin Mao, Wen-qi Chen, Huan-yu Wang, Xu Han, Yuan Ji, Lei Zhang, Da-yong Jin, Wen-Hui Lou and Xue-feng Xu

.1001/jamaoncol.2017.0589 28448665 2 Huguet I Grossman AB O’Toole D. Changes in the epidemiology of neuroendocrine tumours . Neuroendocrinology 2017 104 105 – 111 . ( ) 10.1159/000441897 26505990 3 Yao JC Hassan M

Open access

R C S van Adrichem, L J Hofland, R A Feelders, M C De Martino, P M van Koetsveld, C H J van Eijck, R R de Krijger, D M Sprij-Mooij, J A M J L Janssen and W W de Herder

index. References 1 Modlin IM Oberg K Chung DC Jensen RT de Herder WW Thakker RV Caplin M Delle Fave G Kaltsas GA Krenning EP . Gastroenteropancreatic neuroendocrine tumours . Lancet Oncology 2008 9 61 – 72 . ( doi:10

Open access

Kosmas Daskalakis, Marina Tsoli, Anna Angelousi, Evanthia Kassi, Krystallenia I Alexandraki, Denise Kolomodi, Gregory Kaltsas and Anna Koumarianou

-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study . Lancet: Oncology 2015 16 695 – 703 . ( ) 10.1016/S1470-2045(15)70136-1 5 Strosberg JR Cives M Hwang J Weber T Nickerson M Atreya CE Venook

Open access

Thomas Couronne, Paul Girot, Julien Hadoux, Thierry Lecomte, Alice Durand, Caroline Fine, Katia Vandevoorde, Catherine Lombard-Bohas and Thomas Walter

progression-free survival (PFS) lower than 3–4 months ( 3 , 6 , 7 , 8 , 9 , 10 ). 5-Fluorouracil (5FU) with dacarbazine is an alternative i.v. regimen to oral temozolomide-capecitabine (TEMCAP) regimen for well-differentiated neuroendocrine tumours (NET